MondayApr 10, 2023 9:00 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Revolutionizing Drug Delivery Potential for Active Pharmaceutical Ingredients Using Patented DehydraTECH(TM) Technology

DehydraTECH(TM)-enabled drugs and product formats improve the speed of onset, increase bioavailability, increase brain absorption, enhance drug potency, reduce drug administration costs, and mask unwanted tastes, shown effective with a growing number of medical applications Current DehydraTECH studies (animal and human) include hypertension, dementia, oral nicotine, epilepsy, and diabetes Most recently, Lexaria’s DehydraTECH-CBD studies for hypertension have produced positive results, and the company is seeking IND status with the FDA Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, has developed a disruptive drug delivery technology with multiple opportunities for success in cannabinoids, oral nicotine and other active…

Continue Reading

WednesdayApr 05, 2023 9:00 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Targeting Multiple Commercial Applications for Its Patented DehydraTECH(TM) Technology Platform

Lexaria Bioscience, a global innovator in drug delivery platforms, has developed and patented the DehydraTECH(TM) drug delivery platform technology The company has undertaken multiple studies as part of its extensive R&D program involving DehydraTECH, which continues to yield positive results This R&D program is focused on the development of product candidates across four main segments, which represent the platform’s potential commercial applications These segments include the development of DehydraTECH-processed cannabidiol (“CBD”) for hypertension, epilepsy, diabetes and dementia; DehydraTECH-processed oral nicotine; other pharmaceutical areas exploring a wide range of DehydraTECH-processed active molecules; and hemp-derived CBD applications for consumer packaged goods (“CPG”)…

Continue Reading

TuesdayApr 04, 2023 10:30 am

Cepton, Inc. (NASDAQ: CPTN) Announces 2022 Financial Results With 65% YoY Growth in Revenues

Cepton, Inc. recently published its 4Q22 and FY22 financial results The company revealed that it had generated FY22 revenues of $7.4 million, up by 65% relative to FY21 results. Furthermore, Cepton guided for FY23 revenues of $15-20 million Cepton is at the forefront of lidar technology development, a position they’ve further consolidated with the recent launch of their award-winning Vista® X-120 Plus sensors Cepton (NASDAQ: CPTN), a Silicon Valley innovator and pioneer within high-performance MMT® lidar solutions, recently announced their financial results for the fourth quarter and full year ending December 31, 2022 (https://ibn.fm/6wp95). The company reported full year 2022…

Continue Reading

MondayApr 03, 2023 9:00 am

Lexaria Bioscience Corp.’s (NASDAQ: LEXX) CEO, Chris Bunka, Confident that 2023 will be Lexaria’s Best Year Ever

Chris Bunka, Lexaria’s CEO, remains confident that 2023 will be Lexaria’s best year ever and has expressed his optimism that the company will continue to build its client base and increase its cash flows as the year progresses In his 2023 letter to stakeholders, the CEO expressed his satisfaction given that the company had delivered on a statement that he made the previous year, lauding his team for meeting objectives that Lexaria had set out to achieve in the 2022 calendar year Through the help of his team, Bunka is committed to making Lexaria one of the top drug delivery…

Continue Reading

WednesdayMar 29, 2023 10:30 am

Market Analysis Endorsement Boosts Prospects of OTR Shipping Optimizer Freight Technologies Inc. (NASDAQ: FRGT)

The multi-billion dollar commerce in B2B international exports within the USMCA (formerly NAFTA) North American trading compact as well as likewise valuable domestic shipments represents a massive market Freight Technologies, also known as Fr8Tech, is innovating tech solutions for shipping efficiency within the USMCA territory The company’s flagship offering under its suite of technology-based solutions is branded Freight App, Inc. (or Fr8App) — a cloud-based freight matching platform that connects producers and carriers and helps them track shipments in real time Investment and research firm Chardan Capital Research recently issued a buy rating for Fr8Tech that highlights the company’s value…

Continue Reading

MondayMar 27, 2023 11:15 am

CISO Global Inc. (NASDAQ: CISO) Committed to Building Client Trust, Attains ‘Highest Standard’ with SOC 2 Certification

CISO achieves SOC 2 Type II certification following annual audit President says company is committed to building relationships of trust with clients Achieving certification symbolizes commitment to safeguarding customers’ data As an industry leader in global cybersecurity and compliance services, CISO Global (NASDAQ: CISO), formerly Cerberus Cyber Sentinel Corp., recently reached a significant milestone (https://ibn.fm/BNFYO). The company announced that it has achieved SOC 2(R) Type II certification following its annual SOC 2 Type II audit. “We believe that the relationship with our clients must be built on trust,” said Ashley Devoto, president and chief information security officer of Cerberus Sentinel.…

Continue Reading

FridayMar 24, 2023 9:45 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Patented DehydraTECH(TM) Drug Delivery Technology Demonstrates Growing List of Potential Applications as Evidenced Through Numerous R&D Programs

DehydraTECH(TM) is suitable for use with a wide range of product formats, including pharmaceuticals, nutraceuticals, and over-the-counter capsules, pills, tablets, topicals, oral suspensions and more The patented technology increases the speed of onset, bioavailability, brain absorption, and reduces drug administration costs Lexaria currently has multiple R&D programs – yielding successful results and further opportunities for additional study models Lexaria Bioscience (NASDAQ: LEXX), a global innovator of drug delivery platforms, is increasing bioavailability and improving the way that active pharmaceutical ingredients (“APIs”) enter the bloodstream by promoting more effective oral delivery with its patented DehydraTECH(TM) technology. DehydraTECH is suitable for use…

Continue Reading

FridayMar 24, 2023 9:00 am

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Hits Key Milestone in Global GBM Clinical Trial with the Enrollment of First Patient in Spain

CNS recently enrolled the first patient in Spain in its ongoing global trial evaluating its lead drug candidate, Berubicin, for the treatment of recurrent glioblastoma multiforme (“GBM”) This milestone is the culmination of years of meticulous planning and execution The enrollment of this first patient follows the opening of 37 clinical trial sites of the 59 sites selected across the United States, Italy, France, Spain and Switzerland CNS Pharmaceuticals (NASDAQ: CNSP), a clinical stage biotechnology company specializing in the development of novel treatments with a focus on brain cancer, glioblastoma and neuro-oncology, just enrolled its first patient in Spain, marking…

Continue Reading

WednesdayMar 22, 2023 10:30 am

Freight Technologies Inc. (NASDAQ: FRGT) Announces Update for Fr8TMS, Focusing on Cross-Border Shipping and Freight Movement Within USMCA Region

Fr8Tech aims to revolutionize the commercial trucking industry by introducing logistics and transportation technology catered to moving freight within the USMCA region more efficiently and cost-effectively The update includes several new features and improvements, including real-time tracking and monitoring of shipments, which will allow shippers to see exactly where their freight is at all times and receive notifications for delays Fr8Tech projects that during 2023, it will hit revenues between $36 million and $42 million, compared to preliminary 2022 revenue of approximately $26 million to $27 million Freight Technologies (NASDAQ: FRGT) (“Fr8Tech”), a technology company developing solutions to optimize and…

Continue Reading

TuesdayMar 21, 2023 9:45 am

First Results from Lexaria Bioscience Corp. (NASDAQ: LEXX) Study Show Marked Gains in Blood Pressure Reduction over Generic CBD Controls

Drug delivery platform developer Lexaria Bioscience has developed its patented DehydraTECH(TM) as a means of transforming pharmaceuticals that increases their bioavailability and speed of efficacy Ongoing testing of DehydraTECH in combination with cannabidiol (“CBD”) is analyzing DehydraTECH’s responsiveness to hypertension conditions that are targeted in heart disease and stroke therapies Partial results from the company’s first study indicate Lexaria’s DehydraTECH platform, when processed with CBD, reduces blood pressure and does so much more rapidly when compared with the generic CBD controls The complete results of the study will be produced as sample and data analyses work are completed  Lexaria is…

Continue Reading

Contact us: (310) 299-1717